小剂量阿帕替尼联合替吉奥/顺铂新辅助化疗对SiewertⅠ型老年贲门癌的近期疗效观察  

Therapeutic effects of low dose apatinib combined with S1/cisplatin neoadjuvant chemotherapy in treatment of SiewertⅠgastric cardia cancer in elderly patients

作　　者：刘鸿章 陈新[2] 何明[2] 刘运江[3] 晏峰 李欣慧 张香梅[4] 赵继东 LIU Hongzhang;CHEN Xin;HE Ming(Department of General Surgery,Baoding First Central Hospital,Hebei,Baoding 071000,China;不详)

机构地区：[1]河北省保定市第一中心医院普外四科,071000 [2]河北医科大学第四医院胸外科 [3]河北医科大学第四医院乳腺中心 [4]河北医科大学第四医院科研中心 [5]河北省沙河市人民医院外科

出　　处：《河北医药》2021年第16期2497-2500,共4页Hebei Medical Journal

基　　金：河北省科技厅科技计划项目(编号:17277747D);河北省科技厅科技计划项目(编号:162777249)。

摘　　要：目的通过观察阿帕替尼联合的新辅助治疗的疗效,为SiewertⅠ型贲门癌的新辅助治疗提供新策略。方法收集2018年1月至2019年1月SiewertⅠ型贲门癌患者72例,常规化疗(新辅助组)或联合阿帕替尼(apa+新辅助组)2周期后行手术治疗,分析患者病理退缩率、R0切除率、术后并发症等差异。结果2组化疗不良反应发生率差异无统计学意义(P>0.05)。全部患者均接受Ivor-Lewis手术,其中微创腔镜手术73.61%(53/72,apa+新辅助组26例,新辅助组27例)。2组R0切除率均为100%,术后并发症发生率差异无统计学意义(P>0.05)。病理反应率优于新辅助组(P=0.034),病理1~2级缓解率apa+新辅助组(n=36,100%)优于新辅助组(n=30,83.33%)(P=0.033);apa+新辅助组术后T分期的T1比例优于新辅助组(P=0.028)。结论小剂量阿帕替尼联合替吉奥/顺铂化疗是SiewertⅠ型贲门癌新辅助治疗的安全、有效手段。Objective To investigate the Therapeutic effects of low dose apatinib combined with S1/cisplatin neoadjuvant chemotherapy in treatment of SiewertⅠgastric cardia cancer(AEG)in elderly patients.Methods A total of 72 elderly patients with SiewertⅠAEG were enrolled in the study,who were divided into control group and observation group.The patients in control group were treated by routine chemotherapy,however,the patients in observation group,on the basis of control group,were treated by apatinib.After two treatment courses,the patients in both groups were treated by surgery.The pathological reaction rate,R0 resection rate,postoperative complicatins were observed and compared between the two groups.Results The patients in both groups underwent Ivor-Lewis surgery,in which,micro-invasive telescopic surgery accounted for 73.61%(53/72),including 27 cases in control group and 26 cases in observation group.The R0 resection rate was 100%in both groups.There was no significant difference in the incidence of postoperative complicatins between the two groups(P>0.05).Moreover the pathological reaction rate and remission rate of pathological 1~2 grade in observation group were superior to those in control group(P<0.05).Conclusion The low-dose apatinib combined with apatinib/cisplatin chemotherapy is a safe and effective neoadjuvant therapy measure for SiewertⅠAEG.

关 键 词：SiewertⅠ型贲门癌 新辅助化疗 阿帕替尼 肿瘤退缩 R0切除术 

分 类 号：R735.2[医药卫生—肿瘤]